Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Phase III studies with ipilimumab have demonstrated survival benefit in both previously treated and treatment-naïve patients with metastatic Melanoma (cutaneous)
The combination of Interleukin-2 + Ipilimumab seems to have an increased CR rate, but this needs to be tested in a randomized trial.
Ipilimumab, an Anti-CTLA-4 / CTLA-4 antibodies, demonstrated improved overall survival (OS).
Robert et al. 2011 New England Journal of Medicine 364(26): 2517-2526
Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pr…